Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label emraclidine safety study in adults with schizophrenia
2024-511441-19-00Phase 2Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of emraclidine in schizophrenia (2 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Treatment-emergent adverse events, Clinically significant changes in safety assessments and 2 more. Started Mar 2024; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2024-511441-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511441-19-00.